Clinical trial
Rebif New Formulation (RNF) Quality of Life (QOL) Study
NCT00472797 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00472797 |
|---|---|
| Title | Rebif New Formulation (RNF) Quality of Life (QOL) Study |
| Official title | A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF) |
| Acronym | RebiQoL |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Rebif New Formulation Non Titrated, Rebif New Formulation Titrated |
| Enrollment | 232 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | May 14, 2007 |
| Last update posted | Aug 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: